The story has been updated to include additional comments.

By Matt Jones

NEW YORK (GenomeWeb News) – The US Food and Drug Administration on Wednesday unveiled plan for ways it will try to improve the path to market for medical devices over the coming year.

The 25-point action plan for 2011 is aimed at streamlining the review process, clarifying when clinical data should be submitted, and establishing a new Center Science Council of senior FDA experts to aid in making decisions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.